Is the Market Bullish or Bearish on Krystal Biotech?
According to Benzinga Pro, Krystal Biotech's peer group average for short interest as a percentage of float is 12.98%, which ...
Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...
Brokers Issue Forecasts for Krystal Biotech FY2026 Earnings
Investment analysts at Chardan Capital issued their FY2026 EPS estimates for Krystal Biotech in a research note issued to ...
PMLive3d
Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
Seeking Alpha6d
KRYS Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the ...
Nasdaq6d
Krystal Biotech Gets Positive CHMP Opinion For Vyjuvek To Treat Dystrophic Epidermolysis Bullosa
(RTTNews) - Krystal Biotech, Inc. (KRYS) Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval ...
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and BioCryst (BCRX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Krystal Biotech (KRYS – Research Report) and ...